Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) CEO John Kao sold 172,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $12.96, for a total transaction of $2,236,896.00. Following the completion of the transaction, the chief executive officer directly owned 618,166 shares in the company, valued at approximately $8,011,431.36. The trade was a 21.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Alignment Healthcare Price Performance
ALHC opened at $12.61 on Friday. The company has a fifty day moving average price of $16.17 and a two-hundred day moving average price of $18.03. The firm has a market capitalization of $2.62 billion, a PE ratio of 66.37 and a beta of 1.11. Alignment Healthcare, Inc. has a 52 week low of $12.39 and a 52 week high of $25.12. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.70 and a current ratio of 1.70.
Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the business posted $0.07 EPS. The firm’s quarterly revenue was up 31.6% on a year-over-year basis. As a group, analysts anticipate that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current year.
Institutional Trading of Alignment Healthcare
Key Headlines Impacting Alignment Healthcare
Here are the key news stories impacting Alignment Healthcare this week:
- Positive Sentiment: CEO John Kao’s sales were conducted under a pre-arranged Rule 10b5-1 plan and were intended to cover tax-withholding obligations tied to vested equity awards, reducing the likelihood that the transactions reflect a negative view of Alignment Healthcare’s business prospects. SEC Form 4 filing
- Neutral Sentiment: Alignment Health’s annual survey reported worsening challenges for seniors related to aging in place, support gaps and medical debt. The announcement highlights issues relevant to the company’s target market but does not provide a direct change to revenue, enrollment or earnings expectations. Alignment Health senior survey
- Neutral Sentiment: Reported short interest was zero shares, with a zero-day short-interest ratio. Because the figures show no measurable short position, they provide little evidence of either bearish positioning or potential short-covering support.
- Negative Sentiment: CEO John Kao sold a combined 557,870 shares across September 10–11, worth approximately $7.1 million, reducing his reported ownership. President Dawn Maroney also sold 122,707 shares for about $1.6 million. Although the transactions were tied to tax obligations, their size and timing can weigh on sentiment and may be contributing to the stock’s decline. SEC Form 4 filing
- Negative Sentiment: Kaplan Fox announced an investigation into Alignment Healthcare for possible securities-law violations. The announcement does not establish wrongdoing, but it introduces legal and reputational uncertainty that can pressure the stock. Kaplan Fox investigation announcement
Wall Street Analyst Weigh In
ALHC has been the topic of a number of recent analyst reports. Barclays reduced their target price on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. UBS Group reaffirmed a “neutral” rating on shares of Alignment Healthcare in a research note on Wednesday, July 8th. TD Cowen reiterated a “buy” rating on shares of Alignment Healthcare in a research report on Monday, August 3rd. Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Alignment Healthcare from $26.00 to $22.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.60.
Read Our Latest Stock Analysis on Alignment Healthcare
About Alignment Healthcare
Alignment Healthcare, Inc is a technology-enabled healthcare company that provides Medicare Advantage health plans and care-management services for older adults. Through its Alignment Health Plan subsidiary, the company offers insurance coverage designed for Medicare-eligible members, including primary and specialty care coordination, prescription drug benefits, preventive services and access to a network of healthcare providers.
The company combines health-plan operations with proprietary technology intended to support personalized care.
Recommended Stories
- Five stocks we like better than Alignment Healthcare
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
